Prognostic and theranostic 18F-FDG PET biomarkers for anti-PD1 immunotherapy in metastatic melanoma: association with outcome and transcriptomics
| العنوان: | Prognostic and theranostic 18F-FDG PET biomarkers for anti-PD1 immunotherapy in metastatic melanoma: association with outcome and transcriptomics |
|---|---|
| المؤلفون: | John S Nemer, Romain-David Seban, Samy Ammari, Fatima-Zohra Mokrane, Yvonne M. Saenger, Grace G. Finkel, Randy Yeh, Eric Deutsch, Laurent Dercle, Lawrence H. Schwartz, Luke W. Barker, Caroline Robert, Robyn D. Gartrell, Amélie Bigorgne, Antoine Moya-Plana, Aurélien Marabelle |
| المصدر: | European Journal of Nuclear Medicine and Molecular Imaging. 46:2298-2310 |
| بيانات النشر: | Springer Science and Business Media LLC, 2019. |
| سنة النشر: | 2019 |
| مصطلحات موضوعية: | Adult, Oncology, medicine.medical_specialty, Metastatic melanoma, Regulatory T cell, Biopsy, medicine.medical_treatment, Programmed Cell Death 1 Receptor, 030218 nuclear medicine & medical imaging, Transcriptome, Young Adult, 03 medical and health sciences, 0302 clinical medicine, Fluorodeoxyglucose F18, Internal medicine, Biomarkers, Tumor, medicine, Humans, Radiology, Nuclear Medicine and imaging, Neoplasm Metastasis, Melanoma, Aged, Retrospective Studies, Aged, 80 and over, business.industry, Retrospective cohort study, General Medicine, Immunotherapy, Middle Aged, Prognosis, medicine.disease, Magnetic Resonance Imaging, Treatment Outcome, medicine.anatomical_structure, Lymphatic system, Positron-Emission Tomography, 030220 oncology & carcinogenesis, Bone marrow, business, Follow-Up Studies |
| الوصف: | An imaging-based stratification tool is needed to identify melanoma patients who will benefit from anti Programmed Death-1 antibody (anti-PD1). We aimed at identifying biomarkers for survival and response evaluated in lymphoid tissue metabolism in spleen and bone marrow before initiation of therapy. This retrospective study included 55 patients from two institutions who underwent 18F-FDG PET/CT before anti-PD1. Parameters extracted were SUVmax, SUVmean, HISUV (SUV-based Heterogeneity Index), TMTV (total metabolic tumor volume), TLG (total lesion glycolysis), BLR (Bone marrow-to-Liver SUVmax ratio), and SLR (Spleen-to-Liver SUVmax ratio). Each parameter was dichotomized using the median as a threshold. Association with survival, best overall response (BOR), and transcriptomic analyses (NanoString assay) were evaluated using Cox prediction models, Wilcoxon tests, and Spearman’s correlation, respectively. At 20.7 months median follow-up, 33 patients had responded, and 29 patients died. Median PFS and OS were 11.4 (95%CI 2.7–20.2) and 28.5 (95%CI 13.4–43.8) months. TMTV (>25cm3), SLR (>0.77), and BLR (>0.79) correlated with shorter survival. High TMTV (>25 cm3), SLR (>0.77), and BLR (>0.79) correlated with shorter survival, with TMTV (HR PFS 2.2, p = 0.02, and HR OS 2.5, p = 0.02) and BLR (HR OS 2.3, p = 0.04) remaining significant in a multivariable analysis. Low TMTV and TLG correlated with BOR (p = 0.03). Increased glucose metabolism in bone marrow (BLR) was associated with transcriptomic profiles including regulatory T cell markers (p |
| تدمد: | 1619-7089 1619-7070 |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::45759326237053ca703c90d0fbdec9c3Test https://doi.org/10.1007/s00259-019-04411-7Test |
| حقوق: | CLOSED |
| رقم الانضمام: | edsair.doi.dedup.....45759326237053ca703c90d0fbdec9c3 |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 16197089 16197070 |
|---|